CytomX Highlights Data from Multiple Probody Pipeline Programs at Investor Event During AACR-NCI-EORTC Conference
BOSTON, Nov. 8, 2015 /PRNewswire/ — CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, highlighted data during an investor event today that demonstrate how its Probody technology improves targeting to create safer and more effective therapies across multiple pipeline programs. …
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on our Probody™ technology platform.
Using our Probody platform to create proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class cancer therapeutics against novel targets.